Biocytogen Boston

Company Drug

Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials

Fineline Cube Jun 5, 2025

Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...

Company

Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts

Fineline Cube Aug 17, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations...

Company Deals

Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform

Fineline Cube Mar 9, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Others

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Company Drug

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen